MARKET

PRQR

PRQR

ProQR
NASDAQ

Real-time Quotes | Nasdaq Last Sale

6.50
+0.09
+1.40%
After Hours: 6.58 +0.08 +1.23% 18:15 05/17 EDT
OPEN
6.51
PREV CLOSE
6.41
HIGH
6.90
LOW
6.35
VOLUME
1.11M
TURNOVER
--
52 WEEK HIGH
9.46
52 WEEK LOW
3.400
MARKET CAP
429.83M
P/E (TTM)
-6.4459
1D
5D
1M
3M
1Y
5Y
Prosight Management, LP Buys Galapagos NV, Kezar Life Sciences Inc, Oscar Health Inc, Sells ...
GuruFocus News · 3d ago
ProQR (PRQR) Reports Q1 Loss, Misses Revenue Estimates
Zacks.com · 05/06 13:05
BRIEF-Proqr Announces First Quarter 2021 Operating And Financial Results
reuters.com · 05/06 12:01
BRIEF-Proqr Therapeutics NV Reports Q1 Loss Per Share EUR 0.25
reuters.com · 05/06 11:41
ProQR Therapeutics Q1 EPS €(0.25), Up From €(0.32) YoY
ProQR Therapeutics (NASDAQ:PRQR) will report on Q1 2021.
Benzinga · 05/06 11:34
ProQR reports Q1 results
ProQR (PRQR): Q1 GAAP EPS of -€0.25.Revenue of €0.14M (-46.2% Y/Y).Press Release
Seekingalpha · 05/06 11:31
ProQR Announces First Quarter 2021 Operating and Financial Results
Phase 2/3 pivotal Illuminate trial of sepofarsen for LCA10 enrollment complete with top-line data anticipated in H1 2022 Positive data reported from the...
GlobeNewswire · 05/06 11:00
ProQR Therapeutics Stock Is Trading Higher On Antisense Oligonucleotide Development Pact
Benzinga · 05/04 13:35
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of PRQR. Analyze the recent business situations of ProQR through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 8 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average PRQR stock price target is 26.45 with a high estimate of 44.54 and a low estimate of 18.22.
EPS
Institutional Holdings
Institutions: 82
Institutional Holdings: 39.20M
% Owned: 59.28%
Shares Outstanding: 66.13M
TypeInstitutionsShares
Increased
15
7.69M
New
12
3.61M
Decreased
5
445.24K
Sold Out
5
1.57M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.79%
Pharmaceuticals & Medical Research
+0.65%
Key Executives
Chairman - Supervisory/Independent Director
Dinko Valerio
Chairman - Management/Chief Executive Officer
Daniel De Boer
Independent Director/Supervisory Board
Bart Filius
Vice President/Director of Investor Relations/IR Contact Officer
Lisa Hayes
Independent Director/Supervisory Board
Theresa Heggie
Independent Director/Supervisory Board
Alison Lawton
Independent Director/Supervisory Board
Antoine Papiernik
Independent Director/Supervisory Board
James Shannon
No Data
About PRQR
ProQR Therapeutics N.V. (ProQR), formerly ProQR Therapeutics B.V., is a pre-clinical stage biopharmaceutical company based in the Netherlands. The Company is engaged in the discovery and development of ribonucleic Acid (RNA)-based therapeutics for the treatment of severe genetic disorders. It designs its therapeutic candidates to specifically target and repair the defective messenger RNA, or Messenger Ribonucleic Acid (mRNA), that is transcribed from a mutated gene in order to restore the expression and function of normal, or wild-type protein. Its product candidates include QR-010, an RNA-based oligonucleotide for the treatment of cystic fibrosis (CF), QR-110, an oligonucleotide and for the treatment of Leber’s congenital amaurosis (LCA).

Webull offers kinds of ProQR Therapeutics NV stock information, including NASDAQ:PRQR real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PRQR stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading PRQR stock methods without spending real money on the virtual paper trading platform.